KR101141951B1 - 흑색종용 다중-항원 벡터 - Google Patents

흑색종용 다중-항원 벡터 Download PDF

Info

Publication number
KR101141951B1
KR101141951B1 KR1020067004548A KR20067004548A KR101141951B1 KR 101141951 B1 KR101141951 B1 KR 101141951B1 KR 1020067004548 A KR1020067004548 A KR 1020067004548A KR 20067004548 A KR20067004548 A KR 20067004548A KR 101141951 B1 KR101141951 B1 KR 101141951B1
Authority
KR
South Korea
Prior art keywords
leu
ser
gly
pro
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067004548A
Other languages
English (en)
Korean (ko)
Other versions
KR20060123083A (ko
Inventor
네일 베린스테인
짐 타르타글리아
마크 파링턴
데니스 파니칼리
린다 그리츠
Original Assignee
테리온 바이오로직스, 인크.
사노피 파스퇴르 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테리온 바이오로직스, 인크., 사노피 파스퇴르 리미티드 filed Critical 테리온 바이오로직스, 인크.
Publication of KR20060123083A publication Critical patent/KR20060123083A/ko
Application granted granted Critical
Publication of KR101141951B1 publication Critical patent/KR101141951B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
KR1020067004548A 2003-09-05 2004-09-03 흑색종용 다중-항원 벡터 Expired - Fee Related KR101141951B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50057203P 2003-09-05 2003-09-05
US60/500,572 2003-09-05
US50400703P 2003-09-18 2003-09-18
US60/504,007 2003-09-18
PCT/US2004/028751 WO2005026370A2 (en) 2003-09-05 2004-09-03 Multi-antigen vectors for melanoma

Publications (2)

Publication Number Publication Date
KR20060123083A KR20060123083A (ko) 2006-12-01
KR101141951B1 true KR101141951B1 (ko) 2012-05-04

Family

ID=34316448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067004548A Expired - Fee Related KR101141951B1 (ko) 2003-09-05 2004-09-03 흑색종용 다중-항원 벡터

Country Status (9)

Country Link
US (1) US8911991B2 (enExample)
EP (1) EP1660119A2 (enExample)
JP (2) JP2007503834A (enExample)
KR (1) KR101141951B1 (enExample)
AU (2) AU2004273034A1 (enExample)
BR (1) BRPI0413334A (enExample)
CA (1) CA2537931A1 (enExample)
IL (1) IL173637A0 (enExample)
WO (1) WO2005026370A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
DK2204186T3 (en) 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US20060217893A1 (en) * 2005-01-07 2006-09-28 Yanbin Li Method for detecting an unknown contaminant concentration in a substance
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
US20100120016A1 (en) * 2006-09-01 2010-05-13 Yanbin Li Methods and systems for detection of contaminants
WO2009042773A1 (en) * 2007-09-25 2009-04-02 University Of Miami Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons
WO2011140284A2 (en) * 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
TWI733719B (zh) * 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
AU2017362730B2 (en) * 2016-11-21 2021-04-08 Nant Holdings Ip, Llc Fractal combination therapy
CN120091101A (zh) 2019-11-18 2025-06-03 谷歌有限责任公司 来自视听流的隐私感知会议室转录

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016342A2 (en) * 2001-08-17 2003-02-27 Aventis Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6770456B1 (en) * 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP4409097B2 (ja) * 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
ES2306670T3 (es) * 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
ATE513913T1 (de) * 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
EP1292694A2 (en) * 2000-06-15 2003-03-19 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
NZ526706A (en) * 2000-11-28 2005-03-24 Wyeth Corp Use of inhibitor of differentiation markers ID-1 and ID-3 for the diagnosis and prognosis of prostate cancer
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2003080800A2 (en) * 2002-03-20 2003-10-02 Aventis Pasteur, Inc. Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003095642A2 (en) * 2002-05-07 2003-11-20 Aventis Pasteur, Ltd. Polyepitopes and mini-genes for cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016342A2 (en) * 2001-08-17 2003-02-27 Aventis Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Human Gene Therapy, 2002, Vol. 13, No. 3, pp. 569-575 *
Vaccine, 2001, Vol. 19, pp. 2571-2575 *
Vaccine, 2001, Vol. 19, pp. 2571-2575*

Also Published As

Publication number Publication date
EP1660119A2 (en) 2006-05-31
JP2007503834A (ja) 2007-03-01
US20060127360A1 (en) 2006-06-15
AU2011200127A1 (en) 2011-02-03
IL173637A0 (en) 2006-07-05
HK1101352A1 (en) 2007-10-18
AU2004273034A1 (en) 2005-03-24
KR20060123083A (ko) 2006-12-01
CA2537931A1 (en) 2005-03-24
JP2011041578A (ja) 2011-03-03
WO2005026370A2 (en) 2005-03-24
JP5373747B2 (ja) 2013-12-18
WO2005026370A3 (en) 2005-06-16
AU2011200127B2 (en) 2012-06-21
US8911991B2 (en) 2014-12-16
BRPI0413334A (pt) 2006-10-10

Similar Documents

Publication Publication Date Title
KR101141951B1 (ko) 흑색종용 다중-항원 벡터
US20240117335A1 (en) Fusion proteins for base editing
CN109021111B (zh) 一种基因碱基编辑器
US6218185B1 (en) Piggybac transposon-based genetic transformation system for insects
JP5363446B2 (ja) 癌の予防または治療のための腫瘍抗原
EP1261704B1 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
JP2011067207A5 (enExample)
CN114835821B (zh) 一种高效特异实现碱基颠换的编辑系统、方法及用途
US6911529B1 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU7507698A (en) Human semaphorin L (H-semal) and corresponding semaphorins in other species
GB2443186A (en) Expression system for mediating alternative splicing
EP1496939B1 (en) Modified cea nucleic acid and expression vectors
CN111607614A (zh) 白喉毒素调控清除免疫细胞的cd45-dtr转基因小鼠的构建方法与应用
CN111149730B (zh) 一种快速培育多能干细胞荧光标记斑马鱼纯合个体的方法
CN113789348B (zh) 一种apex2基因敲入的小鼠动物模型、构建方法及其应用
KR20240131976A (ko) 뇌 조직으로 유전자를 전달하기 위한 조성물 및 이의 용도
CN111991550B (zh) Hip-55在制备用于诊断和防治心肌缺血再灌注损伤产品中的应用
WO2001049832A2 (en) Transduction of recombinases for inducible gene targeting
CN111965367A (zh) Hip-55在作为gpcr偏向药物靶点中的应用
KR102009268B1 (ko) 구제역 C3 Resende 주의 방어 항원이 발현되는 재조합 바이러스
Boon et al. Genes coding for tumor-specific rejection antigens
AU2004280608B2 (en) Modified CEA/B7 vector
CN112480249B (zh) Akt新底物hip-55的磷酸化抗体产品制备方法与应用
CN112251413B (zh) 一种跨膜表达新型冠状病毒抗原的细胞的制备方法、细胞和应用
RU2804334C2 (ru) Применение tpk в качестве мишени при болезни альцгеймера

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160426

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160426